All articles tagged with #gemcitabine
The FDA has approved INLEXZO™, a new intravesical system for treating certain bladder cancers, offering a bladder-preserving option for patients unresponsive to BCG therapy, with promising clinical trial results showing high response rates and manageable safety profile.
Pembrolizumab, an immune checkpoint inhibitor, in combination with gemcitabine and cisplatin, has been found to improve overall survival in patients with advanced biliary tract cancer compared to gemcitabine and cisplatin alone, according to a phase 3 trial. The study involved 1,069 patients and found that the pembrolizumab group had a median overall survival of 12.7 months compared to 10.9 months in the placebo group. The combination therapy could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer.